Patent ID: 11918648
Assignee: TRISALUS LIFE SCIENCES, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method for treating cancer in an individual comprising administering to the individual a combination therapy which comprises a PD-1 antagonist and a TLR9 agonist, wherein:
the PD-1 antagonist is a monoclonal antibody, or antigen binding fragment thereof, which comprises: (a) light chain CDRs of SEQ ID NOs: 1, 2 and 3 and heavy chain CDRs of SEQ ID NOs: 4, 5 and 6; or (b) light chain CDRs of SEQ ID NOs: 7, 8 and 9 and heavy chain CDRs of SEQ ID NOs: 10, 11 and 12; and
the TLR9 agonist is a CpG-C type oligonucleotide, wherein the CpG-C type oligonucleotide comprises 5′-TCG Nq TTCGA ACG TTC GAA CGT TCG AAT-3′ (SEQ ID NO: 66), wherein N are nucleosides and q=4.